未登录

E

Esther H. Chang

Department of Oncology

H指数:56

被引数:1.1万

浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enhanced Delivery of Aurora Kinase A Inhibitor Alisertib via Tumor-Targeting Immunoliposome Nanocomplex for Improved Treatment of Cancers Including Atypical Teratoid/Rhabdoid Tumor

通过肿瘤靶向免疫脂质体纳米复合物增强Aurora Kinase A抑制剂Alisertib的递送，以改善包括不典型畸胎瘤/横纹肌样瘤在内的癌症治疗

International Journal of Nanomedicine

IF6.5

2026-01-080

OAAI

RELT Is Upregulated in Breast Cancer and Induces Death in Breast Cancer Cells

IF3.9

2024-11-220

OAAI

SMARCB1 Gene Therapy Using a Novel Tumor-Targeted Nanomedicine Enhances Anti-Cancer Efficacy in a Mouse Model of Atypical Teratoid Rhabdoid Tumors

INTERNATIONAL JOURNAL OF NANOMEDICINE

IF6.5

2024-06-010

OAAI

The role of RELTfms and FLNA in human cancer and cellular apoptosis

CANCER RESEARCH

IF16.6

2024-03-220

PRE

A Pralidoxime Nanocomplex Formulation Targeting Transferrin Receptors for Reactivation of Brain Acetylcholinesterase After Exposure of Mice to an Anticholinesterase Organophosphate

INTERNATIONAL JOURNAL OF NANOMEDICINE

IF6.5

2024-01-012

OAAI

RELT is overexpressed in human inflammatory bowel disease and breast cancer

JOURNAL OF IMMUNOLOGY

IF3.4

2023-05-010

OA

A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models

IF5.2

2022-10-317

OAAI

TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19

IF3.5

2022-03-3120

OAAI

A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma

携带p53基因的靶向肿瘤的纳米药物穿过血脑屏障并增强胶质母细胞瘤小鼠模型的anti-PD-1免疫治疗

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2019-07-0862

OAAI

Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors

IF5.1

2019-04-2317

OAAI

Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor

IF6.3

2018-08-0148

OAAI

Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and novel therapeutic nanomedicine in head and neck cancer

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53-and STING-dependent mechanisms

IF6.3

2018-05-0727

OAAI

Nanotherapeutics for Gene Modulation that Prevents Apoptosis in the Brain and Fatal Neuroinflammation

MOLECULAR THERAPY

IF12

2018-01-0119

OAAI

Cost estimate and budget impact analysis of implementing the new guidelines for management of hepatitis C virus in China: a micro-costing study

IF88.5

2017-12-011

PREAI

Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide

NUCLEIC ACIDS RESEARCH

IF13.1

2017-11-30110

OAAI

BLID is a novel drug-inducible apoptotic molecule: Identification of an integrative mechanism of chemosensitivity in breast cancer cells

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study

MOLECULAR THERAPY

IF12

2016-09-0186

OAAI

A Phase I Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers

SGT-94，泌尿生殖系统肿瘤靶向全身纳米递送系统的I期研究

MOLECULAR THERAPY

IF12

2016-08-0147

OAAI

Systemic administration using targeted gene delivery with SGT-RB94 shows evidence of tumor targeting and anticancer activity: a phase I first-in-man trial

CANCER RESEARCH

IF16.6

2016-07-150

PRE